147P Immune checkpoint inhibitors and hemophagocytic lymphohistiocytosis: Disproportionality analysis from FAERS
Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening immune activation syndrome increasingly reported with immune checkpoint inhibitors (ICIs). Although case reports exist, large-scale pharmacovigilance data comparing PD-1 and PD-L1 inhibitors are limited.
Authors
- S. Atak
- N.S. Demirci
- S.S. Guzel
- E. Cicek
- O. Alan
Institutions
- Istanbul University-Cerrahpaşa (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101231
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00